Clinical Trial Update: Safety of Cotrimoxazole in HIV- and HAART-exposed Infants [Phase 4]

View source ↗

Summary

Phase 4 safety evaluation of cotrimoxazole (sulfamethoxazole-trimethoprim) in HIV- and HAART-exposed newborns has completed, noting safety events such as anemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Anemia
• HIV Infection
• Neutropenia

Drugs mentioned

• Cotrimoxazole (trimethoprim-sulfamethoxazole)

Snippet

Sponsor: Harvard School of Public Health (HSPH) | Conditions: Acquired Immunodeficiency Syndrome, Infant, Newborn | Phase 4 | Status: COMPLETED